MAGE-6 (290-298)

MAGE-6 (290-298) is a synthetic peptide fragment derived from the melanoma-associated antigen 6 (MAGE-6) protein, corresponding specifically to amino acid residues 290 through 298 of the full-length sequence. As a member of the cancer/testis antigen family, MAGE-6 is predominantly expressed in various tumor cells and certain reproductive tissues, making its peptide epitopes of significant interest in immunological and oncological research. The 290-298 fragment is particularly notable for its ability to represent a well-defined, minimal epitope, enabling precise investigation of antigen presentation, T-cell recognition, and peptide-MHC binding dynamics. Its defined sequence and immunogenic relevance position it as a valuable tool for studies focusing on tumor immunology, peptide vaccine development, and the broader field of antigen processing.

Epitope mapping: MAGE-6 (290-298) is frequently utilized in the mapping of T-cell epitopes, allowing researchers to delineate the specific regions of the MAGE-6 protein that are recognized by cytotoxic T lymphocytes. By employing this peptide in functional assays, scientists can assess the presence and specificity of immune responses against tumor-associated antigens, thus deepening the understanding of immune surveillance mechanisms in cancer biology.

Antigen presentation studies: The defined sequence of this peptide makes it an ideal candidate for investigating peptide-MHC class I interactions. Researchers can use it to load antigen-presenting cells and examine the efficiency of peptide binding and presentation on human leukocyte antigen (HLA) molecules. These studies are critical for elucidating the molecular determinants that govern immune recognition and can inform the rational design of peptide-based immunotherapies.

Peptide-based assay development: Laboratories frequently employ MAGE-6 (290-298) as a standard in the development and validation of immunological assays, such as ELISpot, tetramer staining, or cytotoxicity assays. The use of this synthetic peptide enables the quantification and functional characterization of antigen-specific T-cell populations, providing essential insights into immune monitoring during experimental or preclinical studies.

Cancer immunology research: The peptide's relevance to tumor-associated antigenicity makes it a key component in studies investigating the mechanisms of tumor immune evasion, immunoediting, and the induction of anti-tumor immune responses. Researchers can use this peptide to stimulate T cells derived from patient samples or experimental models, facilitating the exploration of cellular immune responses specific to malignancy-associated antigens.

Peptide synthesis and optimization: MAGE-6 (290-298) serves as a reference sequence in the design and optimization of novel synthetic peptides for research purposes. Its defined structure and immunological relevance provide a template for structure-activity relationship studies, stability testing, and the development of modified peptide analogs with enhanced binding affinity or altered immunogenic properties. Such work underpins the advancement of next-generation peptide reagents for basic research and translational applications in immunology and oncology.

1. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

2. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

3. Emu oil in combination with other active ingredients for treating skin imperfections

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet